Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Genfit S.A.

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

James B. Powell

Laboratory Corporation of America Holdings

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Genfit is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. It specializes in the discovery and development of drugs targeting liver diseases.

Genfit

GENFIT | 13,887 followers on LinkedIn. Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. | GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. 

GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC).

Pascal Prigent

CEO at Aurobac Therapeutics

Florence Sejourne

Chief Corporate Affairs Officer of GENFIT

Jean-Christophe Marcoux

Anne-Helene Monsellato

GENFIT

Sanita Men Bhuyan suffered from ACLF earlier in 2024 and survived it thanks to a liver transplant that was made possible through an experimental change in graft allocation guidance. Sadly, unlike Sanita, very few ACLF patients are considered eligible, nor have enough time, for a transplant. Hence the critical need to discover ACLF treatments that allow liver recovery and expand the liver transplant window. These topics, along with other liver-related subjects, will be discussed next week at the 75th Liver Meeting in San Diego, where GENFIT 's teams will be in attendance. Discover the full story of Sanita's journey through ACLF here : https://lnkd.in/em-efivV #AASLD #LiverTransplant #Transplant #ACLF #LiverDisease

📄 #PressRelease GENFIT Reports Third Quarter 2024 Financial Information 📄 #CommuniquéDePresse GENFIT : Information financière du troisième trimestre 2024 #GENFIT #GNFT #Financialnformation

Cette année encore, pour octobre rose, les équipes de GENFIT s’engagent au travers d’actions de sensibilisation et de prévention au service de la santé des femmes. #OctobreRose #Santé #Cancer #CancerDuSein #Solidarité #LutteContreLeCancer

📢 En 2024, GENFIT et l’Unité mixte de Recherche 1011 ont remporté un appel à projets de Chaire Industrielle, soutenu par la Métropole Européenne de Lille (MEL) et l’ Université de Lille ! Lancé en avril, le projet Chaire HepID-ACLF est une collaboration entre GENFIT et l’UMR 1011, dédiée à l’exploration de nouvelles pistes thérapeutiques pour l’ACLF, une pathologie hépatique sévère encore sans traitement approuvé. En travaillant main dans la main avec des experts scientifiques, nous visons à mieux comprendre la perte d’identité hépatocytaire, un mécanisme potentiellement central dans la défaillance hépatique. Ce partenariat, rendu possible grâce au soutien de la MEL et de l’Université de Lille, allie expertises académique et industrielle pour faire avancer la recherche en santé sur notre territoire. Bravo à guillaume vidal , Manager de projet R&D chez GENFIT, Prof. Bart Staels , Directeur de l’UMR 1011, et au Dr. Jerome Eeckhoute , Chargé de recherche à l’UMR 1011, pour ce projet innovant. 👉 Restez connectés, nous vous en dirons plus très bientôt ! #GENFIT #ChaireIndustrielle #Recherche #Innovation #Santé #UniversitéDeLille #MEL

To celebrate October 17th #WorldOrganDonorDay please listen to DR. Jennifer Lai on the importance of buying ACLF patients more time. To this day, Liver transplantation remains the only treatment, provided that an organ is available and the patient is eligible to receive it. #ACLF #LiverDisease #UnmetNeeds #Transplant https://lnkd.in/eb4yEt5H

Ipsen 's Iqirvo® (elafibranor) has been granted marketing authorization in the UK for Primary Biliary Cholangitis (PBC) – a significant milestone that GENFIT is proud to have contributed to. Another step forward in our commitment to improving the lives of patients with rare liver diseases. “There are many people living with PBC with their needs unmet – be that markers of their disease worsening or symptom burden not being controlled. This can have profound implications for patients and their families, which is why a new treatment option is so vitally important.” said Mo Christie, Head of Patient Services, PBC Foundation. #MHRA #Healthcare #Pharmaceuticals #DrugApproval #PBC #Biotech #LiverDisease To learn more about it : https://lnkd.in/eBDxstr3

This approval marks a historic milestone for GENFIT and strengthens our ability to support our efforts in ACLF, with the objective of being the first to discover a treatment for a disease that currently has none. #LiverDisease #PBC #ACLF #Biotech #DrugDevelopment

Merci à Anne Barloutaud pour cet article sur GENFIT revenant sur nos succès et perspectives. Le lancement d'Iqirvo® d' Ipsen est une étape historique de notre développement et contribuera au financement du pivot stratégique initié vers l’Acute-on-Chronic Liver Failure (ACLF) et d'autres maladies du foie. Pour consulter l'article ➡ https://lnkd.in/ej-UMxWS #Biotech #ACLF #PBC #santé #LiverDisease

We are very proud of the E.U Approval of elafibranor (Iqirvo®), made possible through our partnership with Ipsen. This offers physicians a valuable therapeutic alternative for treating patients with PBC. #PBC #Biotech #LiverDisease #EMA https://lnkd.in/ecShtAg6

📄 #PressRelease GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval 👉 https://lnkd.in/d8bHZnk 📄 #CommuniquéDePresse GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine 👉 https://lnkd.in/e7Jaj5T6 #PBC #GENFIT #GNFT #Ipsen

Metric
Company Name	Genfit S.A.	Biotech 365	Laboratory Corporation of America Holdings	Neovacs S.A.
Symbol	GNFT		LH	ALNEV
MSH ID	COM:GENFIT	COM:BIOTECH-365	COM:LABCORP	COM:NEOVACS
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Financial Services & Finance	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology Business Services	Medical - Diagnostics & Research	Biotechnology
Country	FR	FR	US	FR
Stage				Post-IPO Debt
Employee Count	159		67K	22
Website	genfit.com	biotech-365.com	labcorp.com	neovacs.com
LinkedIn	genfit			neovacs
Founders

Metric
Market Cap	211.56M		16.89B	52.99K
Enterprise Value
Monthly Web Traffic		68
Web Traffic Growth		-0.57
Valuation
Raised Capital				4.77M

Metric
Revenue	30.17M	12.16B	563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit	30.17M	3.15B	-7.13M
EBITDA	-36.86M	1.70B	-7.12M
Operating Income	-38.61M	1.12B	-7.30M
Net Income	-30.52M	418M	-9.24M
EPS	-0.61	4.80	-0.00
Diluted EPS	-0.61	4.77	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.14	0.27	-9.71
Operating Profit Margin	-0.07	0.09	-12.95
EBITDA Margin	-1.22	0.14	-12.64
Net Profit Margin	0.02	0.04	-16.39
Return on Equity	0.02	0.06	-0.12
Return on Assets	0.01	0.03	-0.11
Return on Capital Employed	-0.04	0.09	-0.14

COM:GENFIT

Genfit

Last Close

4.06

25/11 09:21

Market Cap

200.28M

Beta: -

Volume Today

19.50K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		28.87
P/B Ratio		2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	8.21	1.59	5.78
EV Multiple	-5.30	8.77	-0.04

Metric
Days Sales Outstanding	517.98	55.66
Days Payables Outstanding		25.45	1.22K
Days Inventory Outstanding	-0.40	19.25
Operating Cycle	380.00	84.65	11.67K
Cash Conversion Cycle	2.27K	52.97	11.39K
Asset Turnover	0.47	0.77	0.01

Metric
Operating Cash Flow	-59.07M	1.33B	-2.02M
Free Cash Flow	-61.69M	874.10M	-2.24M
Cash Flow to Debt	-0.69	0.26	-1.47
Operating Cash Flow/Sales	-0.73	0.11	-3.59
Free Cash Flow Yield		0.05	-0.00

Metric
Cash & Equivalents	82.16M	536.80M	936.97K
Accounts Receivable		-75.30M
Inventory	4.22K	474.60M
Goodwill		6.14B
Debt to Capitalization	0.51	0.43	0.06
Debt to Assets	0.39	0.37	0.02
Current Ratio	2.95	1.36	2.32
Quick Ratio	3.74	0.82	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue
SG&A to Revenue